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Clinics and pathology 
Disease 
Centroblastic lymphoma is one of 3 morphologic 
variants of diffuse large B cell lymphoma (DLBCL). 
The other 2 variants are Immunoblastic lymphoma and 
anaplastic B-cell lymphoma. 
The disease is not recognized as a separate entity in the 
WHO classification (2008). 
Phenotype/cell stem origin 
The postulated normal counterpart is a germinal centre 
B cell or an activated post germinal centre B cell.  
The immunophenotype may help distinguishing 
germinal centre-derived DLBCL from activated B-cell 
derived DLBCL, the former being CD10+ (>30% of 
the cells), or BCL6+ and IRF4/MUM1-. 
The immunophenotype reproduces that of DLBCL, 
with pan B-cell markers positive, surface and/or 
cytoplasmic Ig positive in the majority of the cases. 
The CD30 antigen is negative. CD5 is positive in 10% 
of the cases. CD10 is expressed in approximately half 
of the cases. 
Epidemiology 
It is the most common morphologic variant of DLBCL. 
Clinics 
The disease runs an aggressive course, as all DLBCL. 
Pathology 
The lymph node section shows an overwhelming 
infiltrate by medium-to-large size cells with vescicular 
nuclei and membrane bound nucleoli. The cytoplasm is 
scanty. In the majority of cases centroblasts are 
admixed with immunoblasts (<90%). 
Treatment 
Chemoimmunotherapy using anti CD20 monoclonal 
antibody rituximab in combination with CHOP or 
CHOP-like regimens is the standard of care. 
Prognosis 
Chemoimmunotherapy may cure 40-60% of the cases 
depending on age and risk factors. 
Cytogenetics 
Cytogenetics molecular 
Because the distinction from other morphologic 
variants of DLBCL is not reproducible it is generally 
accepted that there are no distinctive cytogenetic or 
molecular features with respect to diffuse large B-cell 
lymphoma.  
However, some authors described a more frequent 
occurrence of the t(14;18) than in immunoblastic 
lymphoma (Schlegelberger et al., 1999). 
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